Hengrui Medicine gains approval for atopic dermatitis drug
Jiangsu Hengrui Medicine (SSE:600276) announced that it received a drug registration certificate from the National Medical Products Administration for its innovative drug, SHR0302 (Emasicitinib sulfate tablets), to treat moderate-to-severe atopic dermatitis in adult patients who do not respond well to topical treatments. This approval broadens the application of SHR0302, which was previously approved for active ankylosing spondylitis and rheumatoid arthritis. Meanwhile, the company also announced progress in its share repurchase plan. As of April 9, 2025, Hengrui has repurchased 8,324,544 shares, representing 0.13% of its total share capital, for a total of CNY 363,837,671.80. This includes 1,470,800 shares repurchased since the beginning of April, amounting to CNY 70,330,651.00. The company emphasizes its continued commitment to shareholder value and plans to expedite the repurchase program.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
Supplementary Source Documents
News Alerts
Get instant email alerts when Jiangsu Hengrui Medicine publishes news
Free account required • Unsubscribe anytime